Abstract:Background: The only curative therapy for many primary
immunodeficiencies is HSCT. aGvHD is a serious and potentially fatal
complication of HSCT with an incidence of nearly %50. Furthermore,
involvement of the lower gastrointestinal (LGI) tract is associated with
a poor prognosis. Unfortunately, there isn’t consensus about second-line
therapies for steroid-refractory (SR) aGvHD. Alpha 1 Antitrypsin (AAT)
is one of the second-line therapies. There isn’t a study in pediatric
population with acute SR-GvHD in the … Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.